Business Description
Inno-Gene SA
NAICS : 622110
ISIN : PLINNGN00015
Description
Inno-Gene SA operates a DNA research facility that deals with genetic diagnostics, research and development. The company provides services in the field of genetic medical diagnosis, including diagnosis of microbial infections and innate predispositions.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.78 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.36 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 1.65 | |||||
Beneish M-Score | 9.05 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 136.1 | |||||
3-Year EBITDA Growth Rate | 15.8 | |||||
3-Year FCF Growth Rate | -30.7 | |||||
3-Year Book Growth Rate | 52.4 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 34.65 | |||||
9-Day RSI | 42.52 | |||||
14-Day RSI | 44.58 | |||||
6-1 Month Momentum % | -23.52 | |||||
12-1 Month Momentum % | -66.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.21 | |||||
Quick Ratio | 2.2 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 17821.13 | |||||
Days Sales Outstanding | 669.09 | |||||
Days Payable | 6360.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -1.54 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 97.59 | |||||
Operating Margin % | -255.66 | |||||
Net Margin % | -296.15 | |||||
FCF Margin % | -117.71 | |||||
ROE % | -17.72 | |||||
ROA % | -13.47 | |||||
ROIC % | -12.07 | |||||
ROC (Joel Greenblatt) % | -112.37 | |||||
ROCE % | -17.38 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 18.11 | |||||
PS Ratio | 25.07 | |||||
PB Ratio | 1.73 | |||||
Price-to-Tangible-Book | 1.75 | |||||
EV-to-EBIT | -9.03 | |||||
EV-to-EBITDA | -9.28 | |||||
EV-to-Revenue | 26.82 | |||||
EV-to-FCF | -23 | |||||
Price-to-Projected-FCF | 0.63 | |||||
Price-to-Median-PS-Value | 4.57 | |||||
Price-to-Net-Current-Asset-Value | 3.12 | |||||
Earnings Yield (Greenblatt) % | -11.07 | |||||
FCF Yield % | -4.38 | |||||
Forward Rate of Return (Yacktman) % | 39.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inno-Gene SA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.096 | ||
EPS (TTM) (€) | -0.049 | ||
Beta | -0.69 | ||
Volatility % | 54.7 | ||
14-Day RSI | 44.58 | ||
14-Day ATR (€) | 0.001952 | ||
20-Day SMA (€) | 0.361 | ||
12-1 Month Momentum % | -66.73 | ||
52-Week Range (€) | 0.334 - 1.09 | ||
Shares Outstanding (Mil) | 6.2 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Inno-Gene SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Inno-Gene SA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Inno-Gene SA Frequently Asked Questions
What is Inno-Gene SA(FRA:WQ3)'s stock price today?
The current price of FRA:WQ3 is €0.36. The 52 week high of FRA:WQ3 is €1.09 and 52 week low is €0.33.
When is next earnings date of Inno-Gene SA(FRA:WQ3)?
The next earnings date of Inno-Gene SA(FRA:WQ3) is .
Does Inno-Gene SA(FRA:WQ3) pay dividends? If so, how much?
Inno-Gene SA(FRA:WQ3) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |